RevolKa is a pioneer of next-generation protein engineering. We are committed to the discovery and development of innovative proteins by leveraging our proprietary artificial intelligence-integrated directed protein evolution technology, called aiProtein®. RevolKa is open to research collaboration opportunities with partners and also co-development of our internal assets.
About aiProtein®
RevolKa innovatively integrated directed protein evolution with the transformative digital technology, artificial intelligence (AI) to create a proprietary powerful protein engineering technology, called aiProtein®. aiProtein® remarkably accelerates directed protein evolution and enables to create unprecedented engineered proteins. This platform is a robust solution for biologics engineering, for example, to address issues in developability and manufacturability of therapeutic antibodies. aiProtein® enables multi-dimensional simultaneous engineering for protein properties, such as efficacy, affinity, physicochemical properties, immunogenicity, species cross-reactivity, and so on.
Company Details
- Employees
- 12
- Founded
- -
- Address
- 荒巻字青葉6-6-40, 仙台市青葉区,宮城県 980-0845,japan
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.revolka.com/en/
- HQ
- 仙台市青葉区, 宮城県
Revolka Ltd. Questions
Revolka Ltd.'s website is https://www.revolka.com/en/
Revolka Ltd.'s LinkedIn profile is https://www.linkedin.com/company/revolka-ltd
Revolka Ltd. has
12 employees.
View email and phone details for 12
employees at Revolka Ltd..
Revolka Ltd.'s industry is
Biotechnology Research
Revolka Ltd.'s top competitors are
Nammi Therapeutics, Inc.,
Pittan,
Talus Bio,
Nygen Analytics,
Crosspoint Therapeutics,
Nob Hill Therapeutics,
Photonpharma,
Seed Therapeutics,
Nadmed Ltd.,
Release Therapeutics.
Revolka Ltd.'s categories are Biotechnology Research
Revolka Ltd.'s founding year is 2021
